CapsoVision, Inc. Q1 FY2026 earnings call

• Core Commercial Performance

  • Q1 2026 core CapsuleCam Plus end-user procedural volume grew steadily, reflecting deeper engagement with existing installed accounts and increased routine clinical adoption.
  • Key large GI network customer renewals were secured during the quarter, including Indiana University Health Systems, Providence Health Systems, and GastroHealth, demonstrating strong customer value and long-term relationship strength.
  • As of March 31, 2026, over 167,000 patients have been imaged with CapsuleCam Plus across the U.S. and international markets.
  • The U.S. direct sales team held steady at 26 representatives, supported by 7 regional sales managers and trainers; international expansion continues with a dedicated 4-person team in Germany and new distributor partnerships in high-potential markets.

• Technology & Pipeline Progress

  • The 510(k) regulatory submission for the company's AI-assisted reading capability (branded AI Highlights) for CapsuleCam Plus is complete, with clearance expected around mid-year 2026 ahead of commercial launch.
  • AI Highlights integrates with the cloud-native Capsule Cloud platform to flag frames with suspected pathology, streamlining physician review time while maintaining clinical rigor; early feedback from gastroenterologists has been very positive.
  • The CapsuleCAN (Gen 2 CapsuleCam Colon) multi-cancer screening platform development remains on track, with merging of the second-generation capsule and its AI module expected in Q3 2026; prioritizing Gen 2 positions the company for a more competitive, clinically differentiated market entry.
  • Clinical study enrollment for the Capsule Chem UGI pancreatic cancer screening initiative initiated this week, marking a key milestone for what could be a first-of-its-kind non-invasive pancreatic disease screening solution addressing an unmet clinical need for early detection tools.

• Financial Position

  • The company ended Q1 2026 with $17.9 million in cash and cash equivalents, strengthened by a $14 million private placement completed in March 2026 with participation from new and existing investors, providing flexibility for pipeline development, innovation, and commercial expansion.
  • Operating expenses increased 21% year-over-year to $8.4 million, driven by higher investment in next-generation sensor development (under a partnership with Canon) and clinical trial activity for the Gen 2 CapsuleCam Colon program.

The company currently derives all revenue from its core CapsuleCam Plus product, an ingestible capsule for small bowel gastrointestinal disease screening. For Q1 2026, total company revenue was $2.8 million, consistent with the prior year period. Gross profit for the quarter was $1.3 million, with a gross margin of 48%, down 6 percentage points from 54% in Q1 2025. CapsuleCam Plus unit shipments were 6,229 in Q1 2026, a 3% year-over-year decrease, which was offset by a slight increase in average selling price (ASP) driven by geographic mix shift, resulting in flat total annual revenue. No other product segments contributed revenue in the quarter, as pipeline products are still in development.

• Full-year 2026 research and development spending is expected to be roughly similar to 2025 levels, with elevated investment in the Gen 2 CapsuleCam Colon clinical program continuing through Q3 2026 before trailing off in Q4 2026 as the study concludes.
• Q2 2026 revenue is expected to be higher than Q1 2026 revenue, and full-year 2026 revenue is expected to be higher in the second half of the year than the first half, driven by timing of delayed Q1 shipments, growing customer engagement, and the expected commercial launch of the AI Highlights module for CapsuleCam Plus.
• 510(k) clearance for the AI Highlights AI-assisted reading capability remains on track for mid-year 2026, with commercial launch expected to follow shortly after clearance.

• Forward-looking statements regarding regulatory clearance timelines, clinical study enrollment, product launch timing, and future revenue are subject to material risks that could cause actual results to differ from expectations, as outlined in the company's most recent Form 10-K filed with the SEC.
  • Gross margin declined 6 percentage points year-over-year in Q1 2026 due to ongoing tariffs impacting cost of goods sold, creating pressure on profitability in the near term.
  • Clinical study enrollment timelines for the pancreatic cancer screening program are uncertain, and enrollment could take longer than currently expected.
  • While the company expects no unresolved regulatory issues for the AI Highlights 510(k) submission, final FDA clearance timing is outside management control and could be delayed.

Q: What is the current status of the AI-assisted reading 510(k) FDA submission, and are there any remaining issues to resolve? / A: Management has responded to all previous FDA information requests, and is waiting for a scheduled meeting with the FDA in the coming weeks. There are no known unresolved showstopper issues for the submission. Clearance still remains on track for the mid-year 2026 target.

Q: What are the planned size and expected enrollment timeline for the newly initiated pancreatic cancer clinical study? / A: The study plans to enroll 140 total patients to account for drop-out, targeting 120 patients with high-grade dysplasia or pancreatic cancer, plus 120 healthy control reference images pulled from the company's existing cloud data repository, for a total of 240 evaluated cases. Management expects enrollment to complete much faster than the colon capsule study, but did not provide a firm timeline.

Q: Will operating expenses, particularly R&D spending, trend through 2026, and what will full-year R&D look like compared to 2025? / A: Elevated investment in the Gen 2 colon capsule clinical trial will continue through Q3 2026, and will only begin to trail off in Q4 2026 after the study is completed. Full-year 2026 R&D spending will be very similar to 2025 spending levels, with all other operating expense categories showing only nominal stable growth to support ongoing business needs.

Q: What drove the lower Q1 2026 capsule shipment volume, higher ASP, and lower gross margin, and was there a price increase or forward buying? / A: The 3% year-over-year shipment decline was purely driven by timing: large customer orders that were expected in late March shifted into April (Q2 2026), with no underlying weakness in end-user demand. There was no company-wide price increase; the slight ASP increase came from a minor geographic mix shift to sales in higher-priced international regions. Management confirmed end-user consumption (procedural volume) remains healthy and growing, per cloud-based usage tracking.